Announced today that it has executed its in-licensing option from Novartis Pharma AG of Switzerland, for the development and marketing of ZemabR, an antibody based anti-cancer drug. According to the option and licensing agreement originating from 2003, TopoTarget now holds the world-wide and exclusive rights for the development of this product.
COPENHAGEN, Denmark | Mar 12, 2007 | TopoTarget A/S (CSE: TOPO) announced today that it has executed its in-licensing option from Novartis Pharma AG of Switzerland, for the development and marketing of ZemabR, an antibody based anti-cancer drug. According to the option and licensing agreement originating from 2003, TopoTarget now holds the world-wide and exclusive rights for the development of this product.
"I am happy to announce execution of this option. ZemabR has shown potential as a cancer drug in our preclinical models – and in a pilot study where ZemabR was injected directly into tumors in cancer patients with responses seen in 6 out of 10 patients. ZemabR has also successfully been evaluated in a phase I i.v. clinical trial. We are now ready to proceed in the development of ZemabR and next step will be to explore the possibilities in treating breast cancer patients," says Peter Buhl Jensen, CEO of TopoTarget.
ZemabR is a recombinant antibody-toxin for the treatment of specific types of cancers. This drug targets the ERBB2/HER2 receptor, which plays a central role predominantly in the development of breast cancer, but is also believed to be involved in selected other cancer indications, e.g. head and neck cancer. Initial clinical studies have demonstrated a reduction in tumor size after injection of ZemabR directly into ERBB2/HER2-positive tumors. Following a currently ongoing GMP (Good Manufacturing Practice) compliant production of ZemabR, new clinical studies will commence.
TopoTarget A/S
For further information, please contact:
Dr. Peter Buhl Jensen Telephone +45 39 17 83 41
Chief Executive Officer Mobile +45 21 60 89 22
Tim Corcoran Telephone +44 1235 443 713
Chief Operating Officer Mobile +44 787 656 1027
Background information
About TopoTarget
TopoTarget (OMX – The Nordic Exchange: TOPO) is a biopharmaceutical company, headquartered in Denmark and with subsidiaries in the UK, Germany and the USA, dedicated to finding ”Answers for Cancer” and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer enzyme regulators (mainly HDAC, mTOR, and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule preclinical drug candidates and seven drugs are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. SaveneT is TopoTarget’s first product on the market. In addition to organic growth, TopoTarget consistently looks for opportunities to strengthen and expand its activities through acquisitions and in-licensing. For more information, please refer to <http://www.topotarget.com/> www.topotarget.com
TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management’s current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: the risk that any one or more of the drug development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from nonclinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; TopoTarget’s history of incurring losses and the uncertainty of achieving profitability; TopoTarget’s stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget’s products, processes and technologies; the ability to protect TopoTarget’s patents and proprietary rights; uncertainties relating to commercialization rights; and product liability exposure; We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.
SOURCE: TopoTarget A/S
Post Views: 176
Announced today that it has executed its in-licensing option from Novartis Pharma AG of Switzerland, for the development and marketing of ZemabR, an antibody based anti-cancer drug. According to the option and licensing agreement originating from 2003, TopoTarget now holds the world-wide and exclusive rights for the development of this product.
COPENHAGEN, Denmark | Mar 12, 2007 | TopoTarget A/S (CSE: TOPO) announced today that it has executed its in-licensing option from Novartis Pharma AG of Switzerland, for the development and marketing of ZemabR, an antibody based anti-cancer drug. According to the option and licensing agreement originating from 2003, TopoTarget now holds the world-wide and exclusive rights for the development of this product.
"I am happy to announce execution of this option. ZemabR has shown potential as a cancer drug in our preclinical models – and in a pilot study where ZemabR was injected directly into tumors in cancer patients with responses seen in 6 out of 10 patients. ZemabR has also successfully been evaluated in a phase I i.v. clinical trial. We are now ready to proceed in the development of ZemabR and next step will be to explore the possibilities in treating breast cancer patients," says Peter Buhl Jensen, CEO of TopoTarget.
ZemabR is a recombinant antibody-toxin for the treatment of specific types of cancers. This drug targets the ERBB2/HER2 receptor, which plays a central role predominantly in the development of breast cancer, but is also believed to be involved in selected other cancer indications, e.g. head and neck cancer. Initial clinical studies have demonstrated a reduction in tumor size after injection of ZemabR directly into ERBB2/HER2-positive tumors. Following a currently ongoing GMP (Good Manufacturing Practice) compliant production of ZemabR, new clinical studies will commence.
TopoTarget A/S
For further information, please contact:
Dr. Peter Buhl Jensen Telephone +45 39 17 83 41
Chief Executive Officer Mobile +45 21 60 89 22
Tim Corcoran Telephone +44 1235 443 713
Chief Operating Officer Mobile +44 787 656 1027
Background information
About TopoTarget
TopoTarget (OMX – The Nordic Exchange: TOPO) is a biopharmaceutical company, headquartered in Denmark and with subsidiaries in the UK, Germany and the USA, dedicated to finding ”Answers for Cancer” and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer enzyme regulators (mainly HDAC, mTOR, and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule preclinical drug candidates and seven drugs are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. SaveneT is TopoTarget’s first product on the market. In addition to organic growth, TopoTarget consistently looks for opportunities to strengthen and expand its activities through acquisitions and in-licensing. For more information, please refer to <http://www.topotarget.com/> www.topotarget.com
TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management’s current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: the risk that any one or more of the drug development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from nonclinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; TopoTarget’s history of incurring losses and the uncertainty of achieving profitability; TopoTarget’s stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget’s products, processes and technologies; the ability to protect TopoTarget’s patents and proprietary rights; uncertainties relating to commercialization rights; and product liability exposure; We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.
SOURCE: TopoTarget A/S
Post Views: 176
